GlassScriptPhysician profile
Crystal J Mumford
NPI 1619133907
$648.64
in general payments reported to CMS, 2019-2025
13 companies · $86.62 in 2025
The $86.62 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.87 · 2022: $167 · 2023: $86.88 · 2024: $209 · 2025: $86.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $109.90 | 2023-2024 | V-Loc 180, Venaseal, Abre |
| Bard Peripheral Vascular, INC. | $98.87 | 2021 | |
| Baxter Healthcare | $98.81 | 2022-2023 | Preveleak |
| Janssen Pharmaceuticals, INC | $63.68 | 2022 | |
| Kerecis Limited | $48.00 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Convatec INC. | $44.48 | 2024 | |
| Pfizer INC. | $43.37 | 2025 | |
| Solventum Corporation | $34.82 | 2024-2025 | Activ.A.C., V.A.C.Ulta |
| Silk Road Medical, INC. | $26.68 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Atricure, INC. | $24.64 | 2022 | |
| Abbott Laboratories | $23.48 | 2024 | Esprit |
| W. L. Gore & Associates, INC. | $17.28 | 2024 | Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Ethicon US, LLC | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Mumford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.